|
|
 |
|
Viewing report
|
|
|
|
Forecast Insight: Dyslipidemia - Genericization and Negative Trial Data Drive Market Shrinking
Datamonitor, Aug 2008, Pages: 80
The antidyslipidemic market is expected to fall to $20 billion in 2017. The decline will be driven by the deep genericization of the market, further exacerbated by the patent expiries of the top antidyslipidemic, Pfizers Lipitor, as well as by the recent negative messages from the ILLUMINATE and ENHANCE clinical trials.
Scope
- Description of the competitive landscape in antidyslipidemics across seven major markets with market definition and overview.
- Event-driven updated sales forecasts for 2008-17 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan.
- Analysis of major events and brand dynamics affecting the antidyslipidemics market.
Highlights of this title
Some 40% of the entire seven major market antidyslipidemic market is commanded by Lipitor, the gold standard therapy and highest selling agent among statins and antidyslipidemics in general. This will change dramatically after the loss of its patent protection in 2010/2011, reducing Lipitors market share to 9% only by 2017.
The top 10 brands accounted for 81% of the market in 2007; the top revenue generating agents include Lipitor, Vytorin, Crestor, Zetia and Tricor. Over the forecast period the share of the brands in the antidyslipidemic market is expected to fall due to the further genericization.
The recent ENHANCE trial results have added to the distressing effects of genericization, while at the same time curbing the sales of Zetia and Vytorin, and further undermining confidence in the surrogate markers of atherosclerosis. This event is likely to make the ever-stricter process of approval for new agents even harder.
Key reasons to purchase this title
- Quantify the future size and understand the background of the antidyslipidemic market
- Understand the commercial landscape in terms of new product potential
- Understand the barriers to uptake for novel antidyslipidemics.
Customers who bought this item also bought
Strategic Perspectives: Antidyslipidemics - Current Market is not Conducive for Growth
Commercial Insight: Antidyslipidemics - The competitive cost-conscious antidyslipidemics market presents challenges
Antidyslipidemics - Genericization and Negative Trial Data Drive Market Shrinkage
Commercial Insight: Antidyslipidemics - Branded Statins Beware, Generics Are Amongst You
Commercial Insight: Antidyslipidemics - Statins Hit the Brakes on Market Growth
Antidyslipidemics - Cholesterol Absorption of Lipitors Dominance
Pipeline Insight: Dyslipidemia - Pipeline Agents Unlikely To Rejuvenate The Market
The World Market for Gynaecology, 2007-2017
Antidyslipidemics - The Power Of Two
The Subsea Processing Gamechanger Report 2008-2017
Pipeline Insight: Antidyslipidemics - The Power of Two
Dyslipidemia - Statins Dominate Treatment Pathway - For Now
|
|
|
|
